FOCL EDAP TMS SA
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1041934 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin44.4%
Operating margin-31.8%
Net margin-42.8%
FCF margin—
EBITDA margin-27.4%
Returns
ROE-129.2%
ROA—
ROIC (approx.)-176.5%
Asset turnover—
Leverage & solvency
Liabilities / assets67.5%
Debt / equity0.99x
Current ratio2.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|
| Income statement | ||
| Revenue | $70.53M | $69.39M |
| Cost of revenue | $40.53M | $40.65M |
| Gross profit | $30.00M | $28.74M |
| R&D expense | $9.66M | $8.36M |
| SG&A expense | $17.72M | $15.24M |
| Operating income | -$24.69M | -$22.23M |
| Interest expense | $789,000 | $256,000 |
| Pretax income | -$28.81M | -$20.27M |
| Income tax | $438,000 | $313,000 |
| Net income | -$29.25M | -$20.58M |
| EBITDA | -$21.29M | -$19.45M |
| EPS (basic) | -0.78 | -0.55 |
| EPS (diluted) | -0.78 | -0.55 |
| Weighted avg. shares (diluted) | 37.44M | 37.29M |
| Balance sheet | ||
| Cash & equivalents | $20.45M | $31.00M |
| Short-term investments | $0 | 0EUR |
| Receivables | $14.95M | $19.32M |
| Inventory | $7.77M | $19.21M |
| Current assets | $57.16M | $72.59M |
| PP&E, net | $8.79M | $7.57M |
| Goodwill | $757,000 | $2.50M |
| Intangibles | $1.79M | $1.13M |
| Total assets | $79.00M | $89.41M |
| Current liabilities | $37.14M | $39.28M |
| Short-term debt | $2.08M | $2.50M |
| Long-term debt | $15.90M | $2.25M |
| Total debt | $17.98M | $4.75M |
| Total liabilities | $59.58M | $46.92M |
| Shareholders' equity | $19.41M | $42.48M |
| Net debt | -$2.47M | -$26.25M |
| Shares outstanding | 37.48M | 37.39M |
| Cash flow statement | ||
| Operating cash flow | -$16.41M | -$14.70M |
| Investing cash flow | -$5.71M | -$4.46M |
| Financing cash flow | $8.61M | $5.02M |
| Depreciation & amortization | $3.41M | $2.78M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.